From Joe Burnett, President & CEO:
- ClearPoint Prism™ Neuro Laser Therapy System: Initial experience with Prism has been positive with early LiTT procedures performed at select sites in the U.S., and for the clinical trial in Sweden. We continue to gain experience in 3T MRIs and plan to expand our label to 1.5T in early 2024.
- Biologics and Drug Delivery: We recently signed an exclusive multi-year licensing agreement of IP from UCSF to develop and commercialize a radially branching cellular delivery platform that can be used in the OR under fluoroscopy or CT, or in the MRI. We believe this tool will help unlock additional cell therapy partners in the pre-clinical and clinical trial phase.
- Education for Physicians and Pharma Partners: We are proud to share the latest installment of our peer-to-peer ClearPoint On-Demand webinar series available. Many thanks to Dr. Rees Cosgrove and Dr. Dennis McNicholl for sharing your extensive knowledge with our newer customers as well as pharma partners who are learning how to position prone and work with anesthesia.
I will join several members of our team at the AANS Annual Meeting in Los Angeles next month. Please reach out if you would like to meet with me and our talented team to hear about our recent launches and innovation pipeline.
Watch Our Latest ClearPoint On-Demand Webinar for Neurosurgeons & Anesthesiologists - Prone Positioning for iMRI: Optimizing Anesthesia Protocols
In case you missed it, you can now stream the latest edition of our ClearPoint On-Demand education webinar series at your leisure. G. Rees Cosgrove, MD and Dennis J. McNicholl, DO share their expertise on how to to access certain targets using prone positioning in the iMRI including how to optimize anesthesia protocols.
Patient Undergoes LiTT Procedure at Skåne University Hospital Using the ClearPoint Prism™ Neuro Laser Therapy System
Hear from a patient who was enrolled in a Glioblastoma clinical trial using the ClearPoint Prism™ Neuro Laser Therapy System at Skåne University Hospital in Lund, Sweden.
In January 2023, the patient suffered a recurrent brain tumor. The team in Lund determined he was candidate for a new clinical study, which allowed his hard-to-reach tumor to be treated by Neurosurgeon Peter Siesjö, MD, PhD using the ClearPoint Prism laser. Two days after surgery, the patient was able to return home. He was the third patient in Europe to undergo a minimally invasive brain tumor ablation procedure with ClearPoint Prism under MRI-guidance.
The Safety & Feasibility of MR-Guided Laser Thermal Ablation of Brain Lesions Study, sponsored by Clinical Laserthermia Systems AB, is a single-center, single-arm, prospective clinical trial evaluating the safety & feasibility of using the minimally invasive MR-guided laser therapy system to ablate tumors in up to 5 Glioblastoma patients.
Visit ClearPoint Neuro at Booth 1229 on April 22-23 for the 2023 AANS Annual Meeting
ClearPoint Neuro will be exhibiting at the 2023 AANS Annual Meeting: Neurosurgeons as Advocates in Los Angeles, California from April 22nd - 23rd.
Stop by Booth 1229 to check out our latest innovations: ClearPoint Prism™ Neuro Laser Therapy System, ClearPoint Software v.2.1, and the ClearPoint Maestro™ Brain Model.
Calling Neurosurgical Fellows/Residents (PGY-3+): Reserve Your Spot in our Upcoming 2023 Clear Education Fellowship Courses
We invite Neurosurgical Fellows or Residents (PGY-3 and above) to join us at our Solana Beach, CA Global Training & Innovation Center to gain hands-on practical knowledge of iMRI-guided surgical techniques from luminary Functional Neurosurgeons. Space is limited so please sign-up today.
Limit of 5 Attendees from countries where ClearPoint has regulatory approval only. Economy travel to be arranged by ClearPoint Neuro.
May 5-7, 2023 (Friday - Sunday)
Faculty: Paul S. Larson, MD, FAANS
Sept. 22-24, 2023 (Friday - Sunday)
Faculty: R. Mark Richardson, MD, PhD
ClearPoint Signs Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform
Under the licensing agreement of IP from UC San Francisco (UCSF) through its Innovation Ventures group ClearPoint will develop and commercialize a radially branching cellular delivery device for use both in the Operating Room under fluoroscopy/CT guidance and under MRI guidance. Preliminary pre-clinical results were published in Molecular Therapy demonstrating successful deposition of cells to multiple targets using the radially branched deployment device in the MRI, guided by the ClearPoint Neuro Navigation platform.1
1 Silvestrini MT, Yin D, Martin AJ, et al. Interventional magnetic resonance imaging-guided cell transplantation into the brain with radially branched deployment. Mol Ther. 2015;23(1):119-129. doi:10.1038/mt.2014.155
"I Have A Lot More Hope For The Future": Watch Our Newest ClearPoint Champion Journey
Oklahoma native Jan McGee was diagnosed with Parkinson’s Disease in 2016, despite having no family history. Hear her personal story of how the illness took control of her life, and how years of research led her to MRI-Guided Deep Brain Stimulation therapy under the care of neurosurgeon Andrew Conner, MD at Oklahoma University Health.
Explore Our Playlist of Past ClearPoint Champion Videos
Meet Us in Los Angeles on May 17-19 at the 2023 ASGCT Annual Meeting (Booth 454)
ClearPoint Neuro is proud to be a sponsor at the 2023 American Society of Gene & Cell Therapy Annual Meeting at the Los Angeles Convention Center in Los Angeles, California from May 16th - 20th.
Come stop by our Booth #454 to see how ClearPoint is dedicated to providing services and solutions for bench top testing, preclinical studies, clinical trials, and commercialization.
Visit our booth to get a list of ClearPoint-enabled posters and sessions and check out the PTC Therapeutics’ Exhibitor Showcase on Wednesday, May 17th at 8:15AM to hear about how ClearPoint can help Enable Clinical Trials.
Join Us in Barcelona on April 12-14 at the Cell & Gene Meeting on the Med
Members from our Biologics and Drug Delivery team will be at the 2023 Annual Cell & Gene Meeting on the Med in Barcelona, Spain from April 12th - 14th. Connect with our team members to learn more about ClearPoint’s solutions for your gene and cell therapy programs.